Lyophilization News and Research

RSS

Freeze-drying, also referred to as lyophilization, is a process that involves freezing a substance at very low temperatures and then extracting liquid via sublimation, converting water from a solid to gaseous state.

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

Scientists make water-free liquid from blood protein

Scientists at the University of Bristol have discovered a way to make a highly concentrated water-free liquid of a key blood protein, myoglobin, opening up the possibility of new types of biomedical materials.

6 Jun 2010

Osprey Biomedical rolls out Eagle Cervical Allograft Series in ATPS Preservation System

Osprey Biomedical, a global spinal allograft bio-implant company announced today it has begun the roll out of its Eagle Cervical Allograft Series being offered in its ATPS Preservation System.

28 May 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for its first quarter ended January 31, 2010. All amounts are in U.S. dollars unless otherwise indicated.

15 Mar 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

New data from PharmAthene's anthrax vaccine program presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C.

5 Dec 2009

Formatech launches new website

Formatech, Inc is pleased to announce the launch of their new website. The redesigned site features detailed information about the variety of services Formatech offers, including: product development, lyophilization development, their signature Stability Fingerprinting® program and cGMP manufacturing capabilities to support clinical trials, to name a few. The site also provides the latest Formatech news, events, case studies and offers detailed information on their recently established Fillanthropy™ Program.

20 Nov 2009

Althea Technologies offers formulation development services

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development.

5 Nov 2009

EnWave receives R&D funding to develop REV dehydration technologies

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that it has received research and development funding from three separate Canadian federal and provincial government agencies totaling $370,000 to continue the Company's development of its Radiant Energy Vacuum ("REV") dehydration technology for food, food cultures, and biopharmaceuticals.

30 Sep 2009

Three antibodies dried using EnWave's freezeREV vial dehydration technology

EnWave Corporation ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology.

25 Sep 2009

Praxair China installs NCOOL system at Shanghai Pharmaceutical

Praxair China has installed its NCOOL™ cryogenic heat exchanger system at Shanghai The First Biochemical & Pharmaceutical Co., Ltd., an affiliate of Shanghai Pharmaceutical (Group) Ltd. This is the first liquid nitrogen supply contract that Praxair China has signed that employs Praxair’s patented NCOOL cryogenic heat exchanger system in a pharmaceutical freeze dryer.

21 Sep 2009

EnWave signs Confidentiality Agreements with food production companies

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that it has signed Confidentiality Agreements with more than 15 food production companies located in North and South America, Europe and Korea to determine the benefits of using its nutraREVTM food dehydration technology in a wide range of new product areas including herbs, mushrooms, bananas, mangos, pineapples, peppers, tomatoes, garlic, snack chips, shrimp, salmon and pet treats.

17 Sep 2009

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.

25 Aug 2009

Alpharx completes lyophilization process for Zysolin

AlphaRx Inc. has announced that it has completed the lyophilization process for Zysolin(TM), allowing the company to proceed to clinical batch material manufacturing for human trials. This process has been solely developed by AlphaRx's scientists and the resulting formulations have been successfully tested in animal studies conducted by the U.S. Army under a Material Transfer Agreement.

17 Aug 2009

Berries show to have a genome-wide effect on the expression of genes involved in cancer development

New research strongly suggests that a mix of preventative agents, such as those found in concentrated black raspberries, may more effectively inhibit cancer development than single agents aimed at shutting down a particular gene.

27 Aug 2008

GlaxoSmithKline acquires vaccine R&D and manufacturing plant in the U.S.

GlaxoSmithKline has announced that it is expanding its ability to increase vaccines supplies for Americans by acquiring a vaccine research and production facility in Marietta, Pennsylvania.

1 Sep 2005

Embryonic stem cells attached to a gel matrix instead of suspended in solution

30 Mar 2004

New storage method amplifies cells available for science

Like many other kinds of cells used in biomedical research, human embryonic stem cells are stored and transported in a cryopreserved state, frozen to -320 degrees Fahrenheit, the temperature of their liquid nitrogen storage bath. But when scientists thaw the cells for use in the lab, less than 1 percent awake from their frigid slumber and assume their undifferentiated state. This 'blank slate' form is characteristic of stem cells and essential for the basic science required before the promising cells are ready for the clinic.

30 Mar 2004